Author:
Feliu J, ,Castañón C,Salud A,Mel J R,Escudero P,Pelegrín A,López-Gómez L,Ruiz M,González E,Juárez F,Lizón J,Castro J,González-Barón M
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR (1988) Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 4: 1323–1330
2. Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A (2002) Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol 13: 1424–1429
3. Cascinu S, Graziano F, Fearrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Batteli N, Sierna S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R (2002) Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 13: 716–720
4. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobero A, Van Cutsem E, Díaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084–2091
5. Clark DR, Raffin TA (1990) Infectious complications of indwelling long-term central venous catheters. Chest 97: 966–972
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献